| Name | Title | Contact Details |
|---|
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.
Global Marketing Resources Inc is a Dunedin, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Life Plus is a Batesville, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OneWorld provides quality affordable health care, and individuals are welcome with or without insurance, including Medicaid and Medicare. OneWorld operates 13 clinical locations in Omaha; including the clinics at the Historic Livestock Exchange Campus, OneWorld West, Northwest Omaha, Cass Family Medicine, OneWorld Bellevue, Crossroads to Health and Recovery at Community Alliance, two mobile dental clinics, four school-based health centers and the South Omaha Learning Community Centers. Established in 1970, OneWorld Community Health Centers, in partnership with the community, provides culturally respectful, quality health care with special attention to the underserved. OneWorld is a federally qualified health center (FQHC) and provides comprehensive primary health care, dental, mental health/ substance abuse services, and affordable medications.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.